Table 6.
Suggestion for the use of G-CSFs in individual cases. Usage of the GCSFs preparation for cervical cancer
| Q19. CCRT for cervical cancera | |
|---|---|
| n = 114 | |
| I recommend G-CSFs on the following day of chemotherapy | 6 (5.2)b |
| After Grade 4 neutropenia developed, I recommend G-CSFs | 23 (20.2) |
| After FN developed, I recommend G-CSFs | 26 (22.8) |
| I recommend G-CSFs to only high risk patients (Less than neutrophilic 100/mm3continues more than 10 days and/or fungal infectious disease) | 35 (30.7) |
| I do not recommend G-CSFs | 24 (21.1) |
CCRT Concurrent Chemoradiotherapy, G-CSF Granulocyte-Colony Stimulating Factor, FN Febrile Neutropenia
aA 30-year-old woman. We plan to concurrent chemoradiotherapy (cisplatin 40 mg/m2 on days 1, 8, 15, 22, 29, and 36) in patients with stage IIB cervical cancer (squamous cell carcinoma)
bNumber (percent)